Comparing Gyre Therapeutics (NASDAQ:GYRE) and Traws Pharma (NASDAQ:TRAW)Defense World · Sep 29, 2026
Traws Pharma Reports Q2 2026 Financial Results and Provides Business HighlightsGlobeNewsWire · Aug 14, 2026
Traws Pharma (NASDAQ:TRAW) Shares Up 4.8% – Here’s What HappenedDefense World · Aug 4, 2026Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.34 | -$0.16 | Beat |
| May 15, 2026 | -$0.92 | -$0.53 | Beat |
| Apr 15, 2026 | -$1.91 | -$0.82 | Beat |
| Nov 13, 2025 | -$9.16 | -$0.34 | Beat |
| Aug 14, 2025 | -$8.75 | -$0.11 | Beat |
| May 15, 2025 | -$8.04 | $2.09 | Beat |